Research interests

  • Cancer immunotherapy

Development and transfer into the clinic of new cancer immunotherapies. Particular focus is given on the exploitation of immunogenic chemotherapy in combination with established and novel immunotherapeutic approaches to improve the rate of clinical responses in cancer patients.

  • Advanced monitoring of immune responses in cancer patients

Assessment of immune proficiency and identification of markers predictive of the response to (immuno)therapy in cancer patients.

  • Pathogenesis and treatment of infection-driven tumors

Characterization of virus-host interactions of pathogenic relevance in the development of tumours associated with Epstein-Barr infection or arising in HIV-infected patients. Development of assays for the identification of individuals at increased risk of infection-driven tumors and development of novel strategies of (immuno)therapy for an improved control of these tumors.

Researcher biography

Prof. Riccardo Dolcetti is a clinician scientist with MD specializations in Oncology and Clinical Immunology with >20 y research experience in cancer cell biology and immunology. His main scientific background and expertise are in the areas of tumour immunology/immunotherapy and infection-driven tumours. He has been the Director of the Cancer Bio-Immunotherapy Division at the CRO-National Cancer Institute of Aviano, Italy, where he had the opportunity to perform cutting-edge science in the fields of pathogenesis and novel immune-based therapies for cancer. His activity was also devoted to the clinical translation of new cancer immunotherapies and the development of diagnostic assays to improve monitoring of cancer immunotherapy responses. At the end of 2015 he relocated from Italy to Brisbane in the position of Research Chair in Cancer Medicine, Diamantina Institute, University of Queensland. He had the privilege to be the President of the Italian Society for Cancer Research in 2012-13. He has >220 publications in peer-reviewed international journals and 20 book chapters.